Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A.

Cell. 2012 Oct 12;151(2):344-55. doi: 10.1016/j.cell.2012.08.038.

2.

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A.

Science. 2011 Nov 25;334(6059):1129-33. doi: 10.1126/science.1206727. Epub 2011 Oct 27.

3.

Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.

Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K, Konopleva M.

Ann Hematol. 2012 Dec;91(12):1861-70. doi: 10.1007/s00277-012-1537-8. Epub 2012 Aug 15.

4.

Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.

Del Poeta G, Bruno A, Del Principe MI, Venditti A, Maurillo L, Buccisano F, Stasi R, Neri B, Luciano F, Siniscalchi A, de Fabritiis P, Amadori S.

Curr Cancer Drug Targets. 2008 May;8(3):207-22. Review.

PMID:
18473734
5.

p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.

Piedfer M, Bouchet S, Tang R, Billard C, Dauzonne D, Bauvois B.

Biochim Biophys Acta. 2013 Jun;1833(6):1316-28. doi: 10.1016/j.bbamcr.2013.02.016. Epub 2013 Feb 26.

6.

Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.

Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS, Wu X, Zhou WH, Huang RW, Liu Q.

J Transl Med. 2011 May 19;9:71. doi: 10.1186/1479-5876-9-71.

7.

TIM3 expression by leukemic and non-leukemic myeloblasts.

Roth CG, Garner K, Eyck ST, Boyiadzis M, Kane LP, Craig FE.

Cytometry B Clin Cytom. 2013 May;84(3):167-72. doi: 10.1002/cyto.b.21080. Epub 2013 Mar 29.

8.

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.

Leukemia. 2012 Apr;26(4):778-87. doi: 10.1038/leu.2011.287. Epub 2011 Nov 8.

9.

c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.

Xia B, Tian C, Guo S, Zhang L, Zhao D, Qu F, Zhao W, Wang Y, Wu X, Da W, Wei S, Zhang Y.

Leuk Res. 2015 Jan;39(1):92-9. doi: 10.1016/j.leukres.2014.11.004. Epub 2014 Nov 15.

PMID:
25443862
10.

[Allogenic transplantation of hematopoietic stem cells in the treatment of children with high-risk acute leukemia].

Starý J, Kobylka P, Sedlácek P, Komrska V, Vávra V, Syrůcková Z, Smísek P, Hrubá A, Korínková P, Matĕjková E, Cukrová V, Dolezalová L, Loudová M, Sejkorová J, Kvĕch J.

Cas Lek Cesk. 1998 Jun 15;137(12):363-7. Czech.

PMID:
9721472
11.

BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.

Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M.

Mol Cancer Ther. 2013 Dec;12(12):2940-9. doi: 10.1158/1535-7163.MCT-13-0692. Epub 2013 Oct 3.

12.

Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia.

Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G.

Leukemia. 1995 Jul;9(7):1191-8.

PMID:
7543174
13.

Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.

Bosman MC, Schuringa JJ, Quax WJ, Vellenga E.

Exp Hematol. 2013 Jun;41(6):530-538.e1. doi: 10.1016/j.exphem.2013.02.002. Epub 2013 Feb 13.

PMID:
23416210
14.

Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.

Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC.

Blood. 1998 Feb 1;91(3):991-1000.

15.
16.

Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.

Wuchter C, Karawajew L, Ruppert V, Büchner T, Schoch C, Haferlach T, Ratei R, Dörken B, Ludwig WD.

Leukemia. 1999 Dec;13(12):1943-53.

PMID:
10602414
17.

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).

Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S.

Blood. 2003 Mar 15;101(6):2125-31. Epub 2002 Nov 7.

18.

Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.

Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N Jr, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M.

Cancer Res. 2006 Apr 1;66(7):3737-46.

19.

Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.

Hassan HT, Zander A.

Acta Haematol. 1996;95(3-4):257-62. Review.

PMID:
8677752
20.

Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.

Högstrand K, Hejll E, Sander B, Rozell B, Larsson LG, Grandien A.

PLoS One. 2012;7(2):e31366. doi: 10.1371/journal.pone.0031366. Epub 2012 Feb 29.

Items per page

Supplemental Content

Write to the Help Desk